Choi You Hee, Kim Ho Yong, Park Jong-Oh, Choi Eunpyo
Korea Institute of Medical Microrobotics, 43-26 Cheomdangwagi-ro, Buk-gu, Gwangju 61011, Republic of Korea.
Department of Mechanical Engineering, Sogang University, 35, Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea.
Int J Mol Sci. 2025 Mar 1;26(5):2234. doi: 10.3390/ijms26052234.
Exosomes are nanosized extracellular vesicles secreted by various cells, including natural killer (NK) cells, and are known for their low toxicity, high permeability, biocompatibility, and strong targeting ability. NK cell-derived exosomes (NK-exos) contain cytotoxic proteins that enhance tumor-targeting efficiency, making them suitable for treating solid tumors such as hepatocellular carcinoma (HCC). Despite their potential in drug delivery, the mechanisms of drug-loaded NK-exos, particularly those loaded with doxorubicin (NK-exos-Dox), remain unclear in HCC. This study explored the anti-tumor effects of NK-exos-Dox against Hep3B cells . NK-exos-Dox expressed exosome markers (CD9 and CD63) and cytotoxic proteins (granzyme B and perforin) and measured 170-220 nm in size. Compared to NK-exos, NK-exos-Dox enhanced cytotoxicity and apoptosis in Hep3B cells by upregulating pro-apoptotic proteins (Bax, cytochrome c, cleaved caspase 3, and cleaved PARP) and inhibiting the anti-apoptotic protein (Bcl-2). These findings suggest that NK-exos-Dox significantly boost anti-tumor effects by activating specific cytotoxic molecules, offering promising therapeutic opportunities for solid tumor treatment, including HCC.
外泌体是由包括自然杀伤(NK)细胞在内的各种细胞分泌的纳米级细胞外囊泡,以其低毒性、高渗透性、生物相容性和强大的靶向能力而闻名。NK细胞衍生的外泌体(NK-exos)含有增强肿瘤靶向效率的细胞毒性蛋白,使其适用于治疗实体瘤,如肝细胞癌(HCC)。尽管其在药物递送方面具有潜力,但在HCC中,负载药物的NK-exos,特别是负载阿霉素的NK-exos(NK-exos-Dox)的作用机制仍不清楚。本研究探讨了NK-exos-Dox对Hep3B细胞的抗肿瘤作用。NK-exos-Dox表达外泌体标志物(CD9和CD63)和细胞毒性蛋白(颗粒酶B和穿孔素),大小在170-220nm之间。与NK-exos相比,NK-exos-Dox通过上调促凋亡蛋白(Bax、细胞色素c、裂解的半胱天冬酶3和裂解的PARP)并抑制抗凋亡蛋白(Bcl-2),增强了Hep3B细胞的细胞毒性和凋亡。这些发现表明,NK-exos-Dox通过激活特定的细胞毒性分子显著增强抗肿瘤作用,为包括HCC在内的实体瘤治疗提供了有前景的治疗机会。